REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. on October 15, 2015, reporting events occurring on October 14, 2015. The filing addresses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board appointments.
Material Changes
The primary material change reported is the election of David C. Stump, M.D., as a Class III director, effective October 14, 2015. Dr. Stump was elected to fill a vacant seat and will serve on the Audit and Nominating and Corporate Governance Committees, replacing Donald J. Hayden, Jr. on the Audit Committee. His initial term expires at the 2018 annual meeting of stockholders.
Compensation and Governance Details
- Initial Grant: Dr. Stump received an option to purchase 25,000 shares of common stock at an exercise price of $17.89 per share (closing price on October 14, 2015). This option vests in equal monthly installments over three years, with acceleration provisions for change of control or death.
- Annual Retainers: Dr. Stump will receive a $35,000 annual retainer for Board service, plus $7,500 for the Audit Committee and $4,000 for the Nominating and Corporate Governance Committee.
- Future Grants: Beginning in 2016, he is eligible for an annual option to purchase 12,500 shares, vesting over one year.
- Indemnification: An indemnification agreement was executed, requiring the Company to indemnify Dr. Stump to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the independence status of Dr. Stump as determined by the Board under SEC and NASDAQ rules.
- Review the Company's Registration Statement on Form S-1 (File No. 333-206430) for the full text of the non-employee director compensation program.
- Confirm the vesting schedule and acceleration triggers for the 25,000 share option grant.
- Check the press release dated October 15, 2015 (Exhibit 99.1) for additional context on the board expansion.